Long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication: a population-based cohort study
- PMID: 34528716
- DOI: 10.1111/apt.16604
Long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication: a population-based cohort study
Abstract
Background: The long-term effects of H. pylori eradication in preventing upper GI bleeding (UGIB) remains unknown.
Aim: To determine the long-term risks of UGIB after H. pylori eradication METHODS: We included all patients who had received clarithromycin-containing triple therapy for the treatment of H. pyliori infection between 2003 and 2012, without subsequent need for re-treatment. We included a propensity score (PS)-matched endoscopy cohort of H. pylori-negative patients as controls. The primary endpoint was the risk of subsequent UGIB. A multivariable Cox model was used to compute the hazard ratio (HR) of UGIB.
Results: We included 62 738 H. pylori-eradicated and 62 738 PS-matched H. pylori-negative patients, with a median follow-up of 8.1 years (IQR 5.5-10.6). The incidence of UGIB was 20.8 (95% CI 19.5-22.1) and 13.6 (95% CI 12.7-14.7) per 10 000 person-years in H. pylori-eradicated and H. pylori-negative patients, respectively. Compared to controls, H. pylori-eradicated patients had a significantly higher risk of UGIB (HR: 1.65, 95% CI 1.49-1.83). The risk of UGIB in H. pylori-eradicated patients increased after the first 2 years of follow up (HR: 2.18, 95% CI 1.91-2.49). Age-stratified analysis showed that patients >45 years had higher UGIB risk, even after eradication.
Conclusions: Despite H. pylori eradication, the long-term risk of UGIB was still higher than in H. pylori-negative control subjects. The protective effects of eradication therapy in preventing UGIB appeared to be limited to younger patients, and to within the first 2 years after eradication.
Keywords: Helicobacter pylori; age; antibiotics; population-based study; upper gastrointestinal bleeding.
© 2021 John Wiley & Sons Ltd.
Comment in
-
Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease. Authors' reply.Aliment Pharmacol Ther. 2021 Nov;54(10):1352-1353. doi: 10.1111/apt.16654. Aliment Pharmacol Ther. 2021. PMID: 34699095 No abstract available.
-
Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease.Aliment Pharmacol Ther. 2021 Nov;54(10):1350-1351. doi: 10.1111/apt.16617. Aliment Pharmacol Ther. 2021. PMID: 34699099 No abstract available.
-
Letter: the hidden reasons of long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication.Aliment Pharmacol Ther. 2022 Feb;55(3):372-373. doi: 10.1111/apt.16736. Aliment Pharmacol Ther. 2022. PMID: 35040165 No abstract available.
-
Letter: the hidden reasons of long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication-authors' reply.Aliment Pharmacol Ther. 2022 Feb;55(3):374-375. doi: 10.1111/apt.16746. Aliment Pharmacol Ther. 2022. PMID: 35040170 No abstract available.
References
REFERENCES
-
- Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156:254-272.e211. 10.1053/j.gastro.2018.08.063.
-
- Abougergi MS, Travis AC, Saltzman JR. The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis. Gastrointest Endosc. 2015;81:882-888 e881.
-
- Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104:1633-1641.
-
- Guo CG, Zhang F, Wu JT, et al. Divergent trends of hospitalizations for upper and lower gastrointestinal bleeding based on population prescriptions of aspirin, proton pump inhibitors and Helicobacter pylori eradication therapy: trends of upper and lower gastrointestinal bleeding. United European Gastroenterol J. 2021;9:543-551.
-
- Li L, Geraghty OC, Mehta Z, Rothwell PM, Oxford VS. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390:490-499.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical